Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety and tolerability study of repeated 200 mcg IPP-201101 plus standard of care in systemic lupus erythematosus
2017-004060-35Phase 3Completed
- Sponsor
- ImmuPharma
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of forigerimod in systemic lupus erythematosus (SLE), sponsored by ImmuPharma. Primary endpoint: Safety and tolerability of IPP-201101 200 mcg every 4 weeks for 24 weeks. Started Jan 2018; status: completed.
02
Drugs
forigerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2017-004060-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004060-35.